High levels of TRIM59 were associated with more advanced bladder cancer features and shorter survival in a study that also examined how TRIM59 relates to PTRF. In cell and mouse models, altering TRIM59 was accompanied by differences in cancer-cell growth, invasion and metastatic burden. Several biochemical and imaging tests supported a physical TRIM59-PTRF interaction and linked TRIM59 expression to lower PTRF protein stability.
The signal in the patient data
TRIM59 was overexpressed in bladder cancer tissues and cell lines. In the internal clinical dataset, higher expression was associated with advanced T stage, higher pathological grade and recurrence, with reported p-values of 0.010, 0.023 and 0.034, respectively. The study found no reported association with age, gender, lesion number or tumor size. It treated results below a two-sided p-value threshold of 0.05 as statistically significant.
High TRIM59 expression was also associated with reduced overall survival, progression-free survival and disease-free survival across the reported bladder cancer cohorts. The corresponding p-values were 0.007, 0.036 and 0.048. Public-data analyses included 19 TCGA bladder cancer cases with matched adjacent normal tissues, while GSE13507 and GSE154261 supplied external survival cohorts. The report does not provide effect sizes, confidence intervals or an independently adjusted prognostic model, so these results describe an association rather than a validated stand-alone test.
What changed in the laboratory
Functional work used T24, UMUC-3 and J82 bladder cancer cells, along with six-week-old male BALB/c nude mice. Each reported mouse group contained five animals. In T24 and UMUC-3 cells, TRIM59 silencing was accompanied by lower proliferation and colony formation, with more cells in the G1 phase and a smaller S-phase fraction. In J82 cells, overexpression was accompanied by greater growth, colony formation and G1/S progression. It also coincided with larger xenograft tumors and higher Ki-67 positivity.
Tests of movement and spread showed the same broad pattern. TRIM59 silencing was accompanied by reduced Matrigel invasion, lower cell motility, changes in EMT markers and less metastatic burden. Overexpression was accompanied by greater invasion, more wound closure, stronger vimentin staining and greater metastatic dissemination.
A physical link between TRIM59 and PTRF
To look for a molecular explanation, the researchers examined proteins found in TRIM59 complexes. PTRF was one of 11 proteins enriched in Flag-TRIM59 immunoprecipitates. Co-immunoprecipitation, microscopy, PLA and GST pull-down assays supported a physical interaction between the two proteins. A change at PTRF lysine 240, written as K240A in the experiments, weakened the binding.
The next experiments pointed to PTRF protein turnover rather than a change in PTRF RNA. Changing TRIM59 expression did not appreciably change PTRF messenger RNA, but it did change PTRF protein abundance. MG132 largely restored PTRF in the assays, while a CHX chase shortened its half-life. A RING-domain mutant of TRIM59 showed weaker ubiquitination than wild-type TRIM59. Exact half-life estimates and quantitative ubiquitination changes were not reported.
Further tests examined which ubiquitin linkage was involved. Substitutions at four PTRF sites, K98, K122, K152 and K317, were associated with reduced ubiquitination and degradation in the TRIM59 assays. A K48R ubiquitin mutant reduced the modification, while K63R had little effect. The pattern supported predominantly K48-linked rather than K63-linked polyubiquitination.
The pathway gets a rescue test
PTRF was lower in bladder cancer tissues and inversely related to cell-cycle activity. Increasing PTRF was accompanied by lower MYC, c-Myc and cyclin D1 expression, as well as lower activity at the MYC promoter. Modulating AKT changed the response to PTRF manipulation. Together, those results supported the proposed PTRF-AKT/c-Myc pathway in the tested models.
Rescue assays tested whether changing PTRF could offset the effects seen after changing TRIM59. PTRF depletion partly offset the growth and invasion suppression associated with TRIM59 silencing, while PTRF re-expression weakened the growth and invasion increase associated with TRIM59 overexpression. In vivo, PTRF knockdown was accompanied by increased tumor volume and weight. The findings make PTRF a plausible intermediary in these models, but do not show that it is the only relevant TRIM59 substrate.
The clinical question remains open
The study did not test therapeutic responsiveness or actionable vulnerabilities. The authors also identify several other gaps: internal follow-up was short, additional TRIM59 substrates were not evaluated, and the animal findings mainly model metastatic colonization rather than the full spontaneous metastatic cascade. Ubiquitination-resistant PTRF mutants were not tested in vivo, so the experiments do not establish whether preventing PTRF ubiquitination alone would abolish TRIM59-associated signaling.
Treatment benefit remains untested. The study also cannot establish whether PTRF is the only relevant TRIM59 substrate or whether preventing PTRF ubiquitination alone would abolish the associated signaling in vivo. Longer follow-up and clinical validation would be needed before the survival associations could support an independent prognostic test.
Paper data and sources
Original title: TRIM59 Drives Bladder Cancer Progression Through E3 Ligase-Dependent K48-Linked Degradation of PTRF.
Authors: Junlin Gan, Xuesong Bai, Aijie Zhang et al.
Journal/Repository: Cancer science
Status: Peer-reviewed
First online: 2026-08-21
DOI: 10.1111/cas.70510
Original paper